The purpose of this study was to determine the effects of soy protein isolate consumption on circulating hormone profiles and hormone receptor expression patterns in men at high risk for developing advanced prostate cancer. Fifty-eight men were randomly assigned to consume 1 of 3 protein isolates containing 40 g/d protein: 1) soy protein isolate (SPI1) (107 mg/d isoflavones); 2) alcohol-washed soy protein isolate (SPI2) (,6 mg/d isoflavones); or 3) milk protein isolate (0 mg/d isoflavones). For 6 mo, the men consumed the protein isolates in divided doses twice daily as a partial meal replacement.
Introduction
Steroid hormones modulate growth of the prostate gland, and elevated levels of androgens have been associated with prostate cancer risk (1, 2) . Consumption of soy foods is thought to contribute to prostate cancer prevention as a result of the hormonal properties of soy isoflavones, either through altered endogenous circulating hormones or hormone-receptor signaling. Cell culture studies have suggested that the isoflavonoids, genistein and equol, exert the most noteworthy hormonal effects. Genistein inhibits the activity of 5a-reductase and 17b-hydroxysteroid dehydrogenase, enzymes required for androgen synthesis (3, 4) . The isoflavonoid equol, a bacterially derived metabolite of the isoflavone daidzein, sequesters dihydrotestosterone (DHT) 8 from the androgen receptor (AR) in rat prostate tissue (5) . Both isoflavonoids accumulate in the prostate gland (6-9) and may mimic or modulate endogenous hormones relevant to prostate carcinogenesis.
Despite evidence from in vitro studies, human intervention studies report inconsistent effects of soy or isoflavone consumption on circulating hormone profiles in men. Although reports show statistically significant suppression of total testosterone (10, 11) , sex hormone binding globulin (SHBG) (12) , DHT (13) , dehydroepiandrosterone (14) , estrone (15) , and free androgen index (13) , and increased concentrations of SHBG (16) and DHT (17) , the majority of the 22 intervention studies to date have not found significant changes in circulating sex steroid hormones . Generally, the studies that report significant changes were carried out in older men for a relatively long duration. None of the published studies reported equol-excretor status effects on circulating hormone response to soy isoflavone interventions in men.
Circulating hormone profiles may fail to accurately reflect prostate tissue exposure, and evaluating hormone receptor expression patterns in the prostate may provide additional evidence concerning the role of soy as a cancer preventive dietary agent. The AR mediates the action of androgens, and AR expression is a potential marker for prostate cancer prognosis (32) . Dietary genistein has been shown to downregulate AR mRNA expression in rodents (33, 34) , and genistein has been shown to suppress AR activity through an estrogen receptor-b (ERb)-dependent mechanism in LNCaP cells (35) . Despite these data, to our knowledge, there are no studies published to date that evaluate the effects of soy protein isolate consumption on AR and ERb expression in men, although one study reported that an isoflavone extract derived from red clover failed to alter AR expression compared with historically matched controls (26) .
The objective of this project was to evaluate the effects of isoflavone-rich soy protein isolate consumption on circulating concentrations of reproductive hormones and prostate tissue markers of estrogen and androgen receptor expression in men at high risk of prostate cancer. The effects of an isoflavone-rich soy protein isolate were compared with those of an isoflavone-poor soy protein isolate to determine whether the isoflavones are the responsible bioactive constituents. The underlying hypothesis was that isoflavone-rich soy protein isolate consumption would reduce circulating hormones, downregulate AR expression, and upregulate ERb expression.
Material and Methods
Subjects. Fifty-eight men, aged 50-85 y, were recruited at the Minneapolis Veteran's Administration Medical Center Urology Clinic from a group of patients that had already undergone a transrectal ultrasound and biopsy. Patients in this study were either at high risk for developing prostate cancer (n ¼ 53), or had low-grade prostate cancer that was being followed by active surveillance (n ¼ 5). Subjects were considered high risk if they had high-grade prostatic intraepithelial neoplasia (PIN) (n ¼ 50) and/or atypical small acinar proliferation (ASAP) (n ¼ 14). The subjects with prostate cancer had Gleason scores of ,6 and were not receiving any other prostate cancer therapy. Subjects were recruited by urologic physicians, and the research nurse reviewed the patients' medical records to determine that eligibility criteria were met. Exclusionary criteria included BMI .40 kg/m 2 , prostate cancer that required medical treatment, prostatitis, alcohol consumption .14 drinks/ wk, soy or milk allergy, regular antibiotic use, or renal insufficiency.
Eighty-seven subjects were screened for the study; 21 chose not to participate after attending the orientation session, and 66 subjects began the study. Eight subjects withdrew from the study before their 3-mo appointment [disliked the study treatment powder (n ¼ 3), inconvenienced by study demands (n ¼ 2), gastrointestinal discomfort (n ¼ 1), chose conventional prostate cancer treatment (n ¼ 1), weight gain (n ¼ 1)]. Three subjects completed 3 mo of the study with good compliance but chose not to finish due to inconvenience of the study demands, and 55 subjects completed the full 6-mo study.
Data from 58 subjects were included in the serum hormone analysis, and 42 subjects were included in the hormone receptor expression analysis. Fewer participants were eligible for the hormone expression analysis because 3 subjects did not undergo the final prostate biopsy [liver cancer diagnosis (n ¼ 1), heart condition (n ¼ 1), not clinically indicated (n ¼ 1)], and 13 subjects had insufficient biopsy tissue at either baseline or postintervention for the analyses. All 58 subjects who completed the study were Caucasian.
Study design. The University of Minnesota Institutional Review Board Human Subjects Committee, the Minneapolis Veterans Affairs Institutional Review Board, and the U.S. Army Medical Research and Materiel Command's Human Subjects Research Review Board approved the study protocol, and all subjects provided informed consent, attended an orientation session, and were provided with a study handbook. During the study orientation, subjects were interviewed and prompted about incidental exposure to dietary isoflavones (e.g., snack bars, shakes, soy nuts, canned tuna, legumes, breads) to determine whether they were soy consumers. Only one participant reported regular soy consumption, but he did not consume soy-containing products for 1 mo prior to beginning the study. The 6-mo intervention study used a randomized, singleblinded, placebo-controlled, parallel design. Free-living subjects supplemented their diets with 1 of 3 randomly assigned protein isolates: 1) soy protein isolate high in isoflavones (SPI1); 2) soy protein isolate that had most of the isoflavones removed by alcohol extraction (SPI2); or 3) milk protein isolate (MPI) (The Solae Company). The protein isolates were consumed in divided doses twice daily and contributed 40 g/d protein and 200-400 kcal/d (1 kcal ¼ 4.184 kJ). The isoflavone content of the protein isolates expressed as aglycone equivalents was 107 6 5.0 mg/d for the SPI1; ,6 6 0.7 mg/d for the SPI2; and 0 mg/d for the MPI (mean 6 SD). The mean distribution of isoflavones was 53% genistein, 35% daidzein, and 11% glycitein in SPI1, and 57% genistein, 20% daidzein, and 23% glycitein in SPI2 as analyzed by Dr. Pat Murphy (Department of Food Science and Human Nutrition, Iowa State University). The packets of protein isolate were numbered and patients were unaware of the treatment protein isolate they had been assigned until all subjects completed the intervention. Only the study coordinators who administered the protein isolates knew the group to which each participant belonged. Compliance was assessed by counting the number of times the patient consumed the protein isolate, as self-reported in recording calendars given to them, and mean compliance was 94%. Dietary and herbal supplements were allowed, and participants were asked to avoid changing dosages or adding new supplements to their regimen during the study. Subjects consumed their habitual diets, and received detailed instructions to exclude soy products to minimize isoflavone consumption from other sources.
Serum collection and analysis. Fasting blood was collected in the morning at 0, 3, and 6 mo. Serum was separated and aliquots were frozen at -70°C until analysis. All serum samples were analyzed for testosterone, free testosterone, DHT, androstanediol glucuronide (3a-AG), androstenedione, dehydroepiandrosterone sulfate (DHEAS), SHBG, estradiol, and estrone. Steroid hormones were analyzed in duplicate by RIA, and SHBG was analyzed by immunoradiometric assay (Diagnostics Systems Laboratories). Hormone analyses were performed in 3 batches and all assays required 125 I-labeled analyte. Intraassay variabilities were 3.7% for testosterone, 4.4% for free testosterone, 6.1% for DHT, 4.5% for 3a-AG, 4.4% for androstenedione, 2.3% for DHEAS, 4.4% for SHBG, 3.9% for estradiol, and 4.3% for estrone. An internal control was utilized to determine variability among batches, and interassay variabilities were between 9 and 30% for all analytes. All 3 serum samples for each participant were analyzed in the same batch.
Urine collection and analysis. To assess equol-producer status, 24-h urine was collected in plastic containers containing 1 g/L of ascorbic acid and separated into aliquots after the addition of sodium azide to a final concentration of 0.1%. Aliquots were frozen at -20°C until analysis. Equol was determined by HPLC and MS as previously described (36) . The intraassay CV for equol was 8.2%, and the interassay CV was 12.5%. Subjects were classified as equol excretors if 24-h urine equol levels exceeded 1000 nmol/d.
Dietary intake and analysis. Food records were completed for 3 d before each clinic visit. A registered dietitian taught study participants how to keep accurate food records. Patients were encouraged to use household scales and volumetric tools and to submit food labels from unusual foods. Study coordinators reviewed each food record for completeness and clarified ambiguities with the participant at each clinic visit. Food records were analyzed with Nutritionist V, version 2.3 (37) , and, for each 3-d food record, mean intakes of energy, macronutrients, saturated fat, cholesterol, fiber, vitamin D, vitamin E, calcium, selenium, and zinc were calculated.
Tissue collection and analysis. Biopsies were performed before the initial screening and at the 6-mo clinical visit. Biopsy cores were formalinpreserved for 24 h and paraffin embedded. The histological diagnoses were determined during a routine pathological evaluation. Immunohistochemistry was performed to assess AR and ERb expression on primarily normal, hyperplastic, or preneoplastic glands collected from eligible study participants. Antigen retrieval was achieved by pressure cooking deparaffinized and rehydrated tissue sections at 103 kPa in citrate buffer. Sections were treated in quenching solution (3% H 2 O 2 in 100% methanol), and then incubated with a protein-blocking solution (10% milk, 5% serum, and 1% BSA). Samples were incubated overnight at 4°C with rabbit polyclonal anti-ERb antibody (ab3577; Abcam; 1:1000) for the ERb assay, or for 30 min at room temperature with the mouse monoclonal anti-AR antibody (AM256-2M; BioGenex; RTU) for the AR assays. Next, the avidin-biotin peroxidase method was carried out (Vectastain Elite ABC kit, Vector Laboratories). Color reaction was developed using diaminobenzidine as the chromagen. Appropriate positive and negative controls were included in all staining runs. Disrupted glands and glands on the edge of tissue sections were excluded from analysis to avoid false positives. A technician without prior knowledge of histological grading scored both the intensity of immunostaining and the percentage of immunopositive areas at 403 magnification using the HSCORE system as previously described (38) (Fig. 1) .
Excluded from analysis. The following data were excluded from statistical analysis: 6-mo dietary intake from one participant reporting unusually low consumption (mean ,500 kcal) (1 kcal ¼ 4.184 kJ) during the 3-d food diary as a result of illness; 3 mo DHEAS that was above normal range (16 mmol/L) and inconsistent with the participant's baseline and 6-mo measurements; all DHEAS measurements from one participant with abnormally high 3-mo and 6-mo DHEAS concentrations (9 and 10 mmol/L, respectively) compared with baseline; and all SHBG measurements from one subject with undetectable SHBG in the serum (,3 nmol/L). One subject did not consume the treatment powder for 3 d prior to his 6-mo appointment as a result of illness, so he was excluded from the 6-mo equol excretion analysis.
Statistical analysis. The data appeared normally distributed and had similar variance among groups. Demographic comparisons between groups were performed with 1-way ANOVA for continuous endpoints, and chi-square for categories of prostate cancer markers. ANCOVA was used to compare groups adjusted for the baseline value of the final endpoint. For androstenedione, the model included a treatment by baseline interaction. Preplanned pairwise comparisons of all groups are reported for each endpoint as dictated by the study hypotheses: each group's adjusted mean (least squares mean) was compared with the other 2 groups' adjusted means. Paired t tests were used to test for significant within-group changes over time. In addition, these covariates were screened as adjusters: baseline body weight, equol excretor status, and energy and nutrient intake. P , 0.05 was considered significant. All analyses were performed using SAS, version 9.1 (39).
Results
Baseline. Baseline anthropometrics, cancer status, and dietary intake did not differ among the groups ( Table 1 ), except that the MPI group had a higher body weight and the SPI2 group consumed significantly more protein, calcium, and zinc at baseline ( Table 2) . Baseline prostate steroid receptor expression patterns ( Table 3 ) and serum hormone and SHBG concentrations ( Table  4) did not differ among the groups.
Anthropometrics and dietary intake. Body weight did not change from baseline to 3 or 6 mo in any group (Table 2) , and the significant differences in body weight among the groups at baseline were maintained. Protein, calcium, and vitamin D intakes increased in all groups during the study as a result of their concentrations in the protein isolates, and the differences in protein, calcium, and zinc intake at baseline were not present at 3 and 6 mo. At 3 mo, total and saturated fat consumption were reduced in the SPI2 group relative to baseline. During the study, energy, carbohydrate, cholesterol, fiber, vitamin E, selenium, and zinc intakes did not change for any group. Dietary and herbal supplement usage did not differ among groups (data not shown). Body weight and protein intake differences among groups were unrelated to altered hormone concentrations or steroid receptor expression patterns.
Steroid receptors. Baseline-adjusted AR expression was lower in prostate biopsies after 6 mo in the SPI1 group compared with the MPI group (P ¼ 0.04) and tended to be lower in the SPI2 group compared with the MPI group (P ¼ 0.09; Table 3 ). AR expression significantly increased from baseline in the MPI group, but not in the other 2 groups. There were no changes from baseline in ERb expression among the groups (Table 3) .
Serum estrogens. The serum estradiol concentration was significantly increased in the SPI2 group at 3 and 6 mo relative to baseline, and by 6 mo, baseline-adjusted estradiol concentrations were significantly higher in the SPI2 group compared with the other 2 groups (Table 4) . Serum estrone was also significantly increased in the SPI2 group at 3 and 6 mo, and was significantly higher than in the MPI group at 3 mo but not at 6 mo.
Serum androgens and SHBG. The serum androstenedione concentration was significantly higher in the SPI1 group than in the MPI group at 3 mo. At 6 mo it was significantly greater than at baseline in the SPI2 group, resulting in a significantly higher concentration than in the SPI1 group (Table 4) . At both 3 and 6 mo, serum DHEAS was higher in the SPI group than in the other 2 groups, and at 3 mo, 3a-AG was higher in the SPI2 group than the other 2 groups. At 3 mo, the DHT concentration decreased from baseline in the SPI group. Serum SHBG concentrations were decreased significantly from baseline at 3 and 6 mo in all groups, with no difference among the groups.
Equol-excretor status and hormone profiles. Equol excretor status was assessed only in the SPI1 group, because only they consumed sufficient daidzein to excrete equol. At 3 mo, there were 4 excretors and 15 nonexcretors, but of this group, only 1 excretor remained at 6 mo [dropped out after 3 mo (n ¼ 1), (5) 2 (11) 1 Values are means 6 SD or n (%). Means in a row with superscripts without a common letter differ, P , 0.05. 2 Subjects were categorized by most advanced prostate cancer marker.
Soy effects on hormones in men 1771 apparently changed status (n ¼ 1), and excluded data (n ¼ 1)]. Baseline characteristics (Supplemental Table 1 ) and serum hormone concentrations at 3 mo (Supplemental Table 2 ) did not differ between excretors and nonexcretors.
Discussion
The present study evaluated men at high risk of prostate cancer to determine the effects of soy protein consumption on serum hormones and prostate tissue steroid receptor expression levels. The major finding was lower AR expression levels and no differences in ERb expression or circulating hormones in men consuming SPI1 compared with those consuming MPI. AR increased significantly from baseline in the MPI group, but did not change from baseline in the soy groups. Because AR expression is expected to increase in this population (40), we infer that SPI1 apparently prevented or suppressed a rise in AR expression. Lower tissue AR expression in the SPI1 group is consistent with research in which dietary phytoestrogens downregulated AR mRNA expression in adult male rats (33, 34, 41) . Our data differ, however, from those of Jarred et al. (26) , who reported no differences in AR expression patterns between radical prostatectomy patients treated with isoflavones and historically matched controls. The inconsistent results between the 2 studies can be explained by several methodological differences. In the study by Jarred et al. (26) , the subjects, who consumed 160 mg/d of isoflavones in extracts derived from red clover, were men with advanced prostatic neoplasms treated for short and varied time periods (7-54 d). The tissue sections studied from the radical prostatectomies taken from treated subjects represented cancerous glandular acinae and were compared with sections of cancers from historically matched controls. Our subjects consumed 107 mg/d of isoflavones in isoflavone-rich SPI, were earlier in the carcinogenesis continuum, were treated for 6 mo each, and all biological samples were evaluated within the same subject before and after the intervention. Furthermore, the gland acinae studied presented either benign, hyperplastic, or preneoplastic tissue. Consumption of SPI1 did not affect ERb expression or circulating hormones. The ERb expression results are inconsistent with studies in animals in which prolonged isoflavone exposure decreased ERb expression (33, 42) , and may be explained by the variability in commercially available ERb antibodies (43) . Our hormone results, however, are consistent with most published reports from the clinical setting. The testosterone results are consistent with numerous soy or isoflavone intervention studies in which no change in total testosterone was observed (12-31), but differ from 2 studies of short duration (10, 11) . Our finding of no effect on directly measured free testosterone is similar to published soy or isoflavone intervention studies to date (11, 14, 15, 20, 22, 24) , and our finding of no effect on circulating DHT is consistent with most reports (10, 14, 16, (19) (20) (21) 23, 30) , although it differs from results of 2 studies (13, 17) , one of which used red clover extract (17) . The lack of effect on circulating estradiol or estrone is consistent with the literature (10, 11, 15, 16, 19, 22, 29, 30) , although there is one report of decreased estrone in men consuming soymilk for 8 wk (15) .
Serum SHBG decreased significantly from baseline in all study groups. The finding that consumption of SPI1 decreased SHBG is similar to a report by Mackey et al. (12) ; however, they did not find a significant decrease in SHBG with an isoflavonepoor protein isolate as we did. In contrast to our findings, Habito et al. (16) reported increased SHBG in men consuming 35 g of tofu daily for 2 wk, and others have reported no significant changes of SHBG with isoflavone-rich foods or extracts (13, 15, 17, (20) (21) (22) (23) 30) . Decreased SHBG is a potentially harmful effect because SHBG-bound hormones are less biologically available to stimulate hormone-sensitive cancers. Because high protein intake has been associated with decreased SHBG (44) , it is likely that the decrease in SHBG from baseline in all groups in our study resulted from the subjects' significantly increased protein intake during the study (45) .
The hormonal effects in the SPI2 group were unexpected. Although AR expression was not significantly lower in the SPI2 group, AR expression appeared to be intermediate between that of SPI1 and MPI groups. In addition, serum estradiol was increased in the SPI2 group. These results are similar to a study in young men by Dillingham et al. (20) in which a low-isoflavone protein isolate containing ,2 mg/d isoflavones significantly increased estradiol and estrone compared with a milk protein isolate after a 8-wk intervention. Our results differ, however, from a study in older men by Goldin et al. (19) in which a low-isoflavone soy protein isolate containing ,2 mg/d isoflavones did not change estradiol or estrone concentrations after a 6-wk intervention. Interestingly, we found serum estradiol was significantly higher in the SPI2 group than in the SPI1 group, whereas in Dillingham et al. (20) found that estradiol in the low-isoflavone group did not differ from the high-isoflavone group (20) .
Serum androstenedione and DHEAS concentrations were increased in the SPI2 group compared with both SPI1 and MPI groups. No other soy protein or isoflavone intervention study has reported a change in circulating androstenedione (12, 17, 19, 20, 30) , but all other studies to date have intervened for a shorter duration. Higher DHEAS is consistent with other low-isoflavone soy protein isolate interventions (19, 20) . Although DHEAS and androstenedione can be converted by 17b-hydroxysteroid dehydrogenase to testosterone, no significant changes were observed in circulating testosterone, free testosterone, or DHT. Instead, our study population had low, but normal, testosterone concentrations throughout the study. Although DHEAS and androstenedione concentrations have been associated with aggressive prostate cancer (46) , our findings of unchanged testosterone and a trend toward lower AR expression (P ¼ 0.09) suggest neutral effects of SPI2 consumption. In fact, because DHEAS and androstenedione may be converted to estradiol and estrone in the prostate gland (47) , the increase in DHEAS and androstenedione may have contributed to the observed increases in circulating estradiol and estrone. The hormonal effects of SPI2 consumption are likely due to the effects of the alcohol extraction process on SPI constituents.
In conclusion, we found that consumption of isoflavone-rich soy protein for 6 mo lowered AR expression levels in the prostate, but did not change ERb expression or circulating hormones in men at high risk of prostate cancer. Although consumption of the alcohol-extracted soy protein did not significantly lower AR expression, its effect appeared to be intermediate to that of SPI1 and MPI consumption, suggesting that the isoflavones alone may not be responsible for the AR expression decrease, or, alternatively, that the low level of isoflavones in SPI2 were sufficient to alter the AR. Unexpectedly, consumption of SPI2, but not SPI1, significantly increased estradiol and androstenedione concentrations. None of these results were influenced by equol excretion status. These data suggest that consumption of isoflavone-rich and isoflavone-poor soy protein isolate exert differing effects on endogenous hormones and receptor expression, which may mediate prostate cancer preventive effects.
